Business Description
Evotec SE
NAICS : 325412
SIC : 2834
ISIN : DE0005664809
Share Class Description:
LTS:0IRF: Ordinary SharesCompare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USAEVT.Austria1EVT.Italy IPO Date
2009-10-10Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.05 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | -9.89 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.45 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year FCF Growth Rate | 21.3 | |||||
| 3-Year Book Growth Rate | 28.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.9 | |||||
| 9-Day RSI | 40.47 | |||||
| 14-Day RSI | 43.42 | |||||
| 6-1 Month Momentum % | -23.87 | |||||
| 12-1 Month Momentum % | -29.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.16 | |||||
| Quick Ratio | 2.09 | |||||
| Cash Ratio | 1.43 | |||||
| Days Inventory | 25.93 | |||||
| Days Sales Outstanding | 93.54 | |||||
| Days Payable | 79.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | -1.93 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 27.44 | |||||
| Operating Margin % | -1.78 | |||||
| Net Margin % | -13.35 | |||||
| FCF Margin % | -13.64 | |||||
| ROE % | -6.86 | |||||
| ROA % | -3.57 | |||||
| ROIC % | -0.84 | |||||
| ROC (Joel Greenblatt) % | -8.71 | |||||
| ROCE % | -3.19 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 62.89 | |||||
| Shiller PE Ratio | 90.67 | |||||
| PS Ratio | 3.92 | |||||
| PB Ratio | 2.09 | |||||
| Price-to-Tangible-Book | 2.8 | |||||
| EV-to-EBIT | -39.52 | |||||
| EV-to-Forward-EBIT | 30.43 | |||||
| EV-to-EBITDA | -39.52 | |||||
| EV-to-Forward-EBITDA | 13.61 | |||||
| EV-to-Revenue | 3.87 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | -28.4 | |||||
| Price-to-Projected-FCF | 2.18 | |||||
| Price-to-Median-PS-Value | 0.58 | |||||
| Earnings Yield (Greenblatt) % | -2.53 | |||||
| FCF Yield % | -3.48 | |||||
| Forward Rate of Return (Yacktman) % | 22.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 607.246 | ||
| EPS (TTM) (€) | -0.45 | ||
| Beta | 1.15 | ||
| Volatility % | 57.17 | ||
| 14-Day RSI | 43.42 | ||
| 14-Day ATR (€) | 0.596199 | ||
| 20-Day SMA (€) | 13.804625 | ||
| 12-1 Month Momentum % | -29.71 | ||
| 52-Week Range (€) | 12.54 - 24.44 | ||
| Shares Outstanding (Mil) | 177.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evotec SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evotec SE Frequently Asked Questions
What is Evotec SE(LTS:0IRF)'s stock price today?
The current price of LTS:0IRF is €13.22. The 52 week high of LTS:0IRF is €24.44 and 52 week low is €12.54.
When is next earnings date of Evotec SE(LTS:0IRF)?
The next earnings date of Evotec SE(LTS:0IRF) is 2024-04-24.
Does Evotec SE(LTS:0IRF) pay dividends? If so, how much?
Evotec SE(LTS:0IRF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers